Comparative Effectiveness of Cladribine and S1P Receptor Modulators in Treatment-Naive Relapsing-Remitting MS.

ABSTRACT:

Importance

Early treatment choice in relapsing-remitting multiple sclerosis (RRMS) is prognostically crucial, yet robust comparative data on cladribine vs sphingosine-1-phosphate receptor modulators (S1PRMs) in treatment-naive patients with RRMS are limited.

Objective

To compare the clinical effectiveness of cladribine vs S1PRMs in treatment-naive individuals with RRMS.

Design, setting, and participants

This comparative effectiveness research study used data from 108 Italian multiple sclerosis (MS) centers affiliated with the Italian Multiple Sclerosis and Related Disorders Register. All treatment-naive patients with RRMS who initiated cladribine or an S1PRM (fingolimod, ozanimod, or ponesimod) between January 2011 and October 2021 and had at least 12 months of follow

SUBMITTER: Haggiag S 

PROVIDER: S-EPMC12584038 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature